Summary of Sana Biotechnology Conference Call Company Overview - **Company**: Sana Biotechnology (SANA) - **Event**: 2025 Bank of America Healthcare Conference - **Date**: May 13, 2025 Key Points on Type One Diabetes - **Disease Impact**: Type one diabetes affects approximately nine million people globally, leading to a reduced lifespan of 10-15 years and significant daily challenges for patients [4][5] - **Unmet Medical Need**: No new drug has been developed for type one diabetes since insulin in 1923, indicating a substantial unmet need for better treatment options [5] - **Current Research**: Sana is focusing on gene-modified pluripotent stem cells to create a scalable source of pancreatic islets for transplantation, aiming to eliminate the need for immunosuppression [10][12] Recent Data and Developments - **Clinical Data**: A patient treated with gene-modified islet cells has been insulin-free for over 30 years, with no signs of immunologic response after 12 weeks [10][12] - **Future Plans**: An Investigational New Drug (IND) application is anticipated next year, with the goal of beginning human treatments [11][12] Challenges and Considerations - **Scaling Production**: Significant work is required to scale the production of gene-modified islets to meet the needs of the nine million affected individuals [18][20] - **Manufacturing Process**: The manufacturing process must be locked in before starting pivotal studies, which is expected to take about a year [29] Other Pipeline Assets - **CAR T Cell Therapy**: Sana is applying hypoimmune technology to develop allogeneic CAR T cells, addressing challenges in the autoimmune setting and aiming for improved patient convenience [31][32] - **Ongoing Studies**: Two studies, Gleam and Vivid, are ongoing, with data expected later this year [30] Market and Financial Considerations - **Investment Landscape**: The company acknowledges the need for increased investment to continue development, particularly in the competitive field of cell and gene therapy [39][40] - **Return on Investment**: The potential for high ROI is emphasized, contingent on successful scaling and safety of the diabetes treatment [43][44] Regulatory Environment - **FDA Interactions**: The company is optimistic about upcoming meetings with the FDA to confirm testing protocols for their gene-modified therapies [17] Conclusion - **Commitment to Diabetes Asset**: Sana Biotechnology is committed to advancing its diabetes treatment while navigating the complexities of scaling production and ensuring safety [42]

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana is likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 Healthcare Conference at 9:20 a.m. PT on Tuesday, May 13, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to alleged misleading statements and financial misrepresentations during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 17, 2023, to November 4, 2024 [3]. - Allegations include that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates, specifically SC291 in oncology, SC379, and SG299, which were less promising than represented [3]. - It is claimed that to preserve cash, Sana was likely to decrease funding for these product candidates and significantly reduce its workforce, leading to overstated financial capacity [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 20, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana Biotechnology was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its workforce to preserve cash for more promising projects [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of SANA during the specified timeframe are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of stock prices [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39941 Sana Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1381173 (State or other jurisdi ...

Exhibit 1.1 SANA BIOTECHNOLOGY, INC. COMMON STOCK SALES AGREEMENT May 8, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Ladies and Gentlemen: Sana Biotechnology, Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with TD Securities (USA) LLC ("TD Cowen"), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue an ...

Core Insights - Sana Biotechnology, Inc. has made significant progress in developing therapies for type 1 diabetes, with promising clinical results indicating that hypoimmune-modified pancreatic islet cells can function without immunosuppression and maintain stable C-peptide production post-transplant [1][2][5] - The company is advancing its pipeline with ongoing trials for SC291 and SC262 targeting B-cell mediated autoimmune diseases and relapsed/refractory B-cell malignancies, respectively, with data expected in 2025 [1][7] - Financially, Sana reported a cash position of $104.7 million as of Q1 2025, with a cash runway expected to extend into 2026 [1][6] Clinical Developments - The ongoing UP421 trial has shown that hypoimmune-modified pancreatic islets can evade immune detection and continue to function three months post-transplant, which is a critical step towards a functional cure for type 1 diabetes [2][5] - Preclinical data for SC451 demonstrated 15-month durability of glycemic control in a mouse model, with no histological abnormalities, supporting its potential for future clinical application [4] - The GLEAM and VIVID trials are currently enrolling patients, with expectations to report clinical data in 2025 [1][7] Financial Performance - For Q1 2025, the company reported a net loss of $49.4 million, or $0.21 per share, a significant reduction from a net loss of $107.5 million, or $0.49 per share, in Q1 2024 [6][14] - Research and development expenses decreased to $37.2 million in Q1 2025 from $56.4 million in the same period in 2024, primarily due to lower personnel-related and clinical development costs [6][14] - The company’s non-GAAP operating cash burn for Q1 2025 was $46.6 million, down from $58.7 million in Q1 2024, indicating improved cash management [10][19]

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zl ...

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=147117&from=3 CLASS PERIOD ...